AU2017384134B2 - Combination of a protein kinase inhibitor and an additional chemotherapeutic agent - Google Patents

Combination of a protein kinase inhibitor and an additional chemotherapeutic agent Download PDF

Info

Publication number
AU2017384134B2
AU2017384134B2 AU2017384134A AU2017384134A AU2017384134B2 AU 2017384134 B2 AU2017384134 B2 AU 2017384134B2 AU 2017384134 A AU2017384134 A AU 2017384134A AU 2017384134 A AU2017384134 A AU 2017384134A AU 2017384134 B2 AU2017384134 B2 AU 2017384134B2
Authority
AU
Australia
Prior art keywords
compound
nci
etoposide
lung
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017384134A
Other languages
English (en)
Other versions
AU2017384134A1 (en
Inventor
Lars DAMSTRUP
Thomas GROMBACHER
Christian Sirrenberg
Lyubomir VASSILEV
Astrid Zimmermann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Publication of AU2017384134A1 publication Critical patent/AU2017384134A1/en
Application granted granted Critical
Publication of AU2017384134B2 publication Critical patent/AU2017384134B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2017384134A 2016-12-19 2017-12-18 Combination of a protein kinase inhibitor and an additional chemotherapeutic agent Active AU2017384134B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662436046P 2016-12-19 2016-12-19
US62/436,046 2016-12-19
PCT/EP2017/083272 WO2018114776A1 (en) 2016-12-19 2017-12-18 Combination of a protein kinase inhibitor and an additional chemotherapeutic agent

Publications (2)

Publication Number Publication Date
AU2017384134A1 AU2017384134A1 (en) 2019-08-01
AU2017384134B2 true AU2017384134B2 (en) 2022-03-24

Family

ID=60915499

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017384134A Active AU2017384134B2 (en) 2016-12-19 2017-12-18 Combination of a protein kinase inhibitor and an additional chemotherapeutic agent

Country Status (8)

Country Link
US (1) US11246929B2 (enExample)
EP (1) EP3554495B1 (enExample)
JP (1) JP7113826B2 (enExample)
KR (1) KR102607967B1 (enExample)
AU (1) AU2017384134B2 (enExample)
CA (1) CA3047449C (enExample)
ES (1) ES3040063T3 (enExample)
WO (1) WO2018114776A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102013008118A1 (de) * 2013-05-11 2014-11-13 Merck Patent Gmbh Arylchinazoline
KR20220027183A (ko) * 2019-06-27 2022-03-07 메드샤인 디스커버리 아이엔씨. Dna-pk 억제제로서의 퀴놀린 및 시놀린 유도체
CN116670128A (zh) * 2020-12-28 2023-08-29 南京明德新药研发有限公司 吗啉取代的苯并嘧啶类化合物的晶型及其制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130281431A1 (en) * 2012-04-24 2013-10-24 Vertex Pharmaceuticals Incorporated Dna-pk inhibitors
US20160083401A1 (en) * 2013-05-11 2016-03-24 Merck Patent Gmbh Arylquinazolines

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8710095B2 (en) 2002-04-30 2014-04-29 Bionumerik Pharmaceuticals, Inc. Drugs for prophylaxis or mitigation of taxane-induced neurotoxicity
CN1861050A (zh) 2006-06-21 2006-11-15 山东蓝金生物工程有限公司 一种同载铂类化合物及其增效剂的抗癌药物缓释注射剂
PE20090678A1 (es) 2007-09-12 2009-06-27 Genentech Inc Combinaciones de compuestos inhibidores de fosfoinositida 3-quinasa y agentes quimioterapeuticos y los metodos de uso
AU2009221808A1 (en) 2008-03-06 2009-09-11 Genentech, Inc. Combination therapy with c-met and EGFR antagonists
KR102411227B1 (ko) 2013-10-17 2022-06-21 버텍스 파마슈티칼스 인코포레이티드 Dna-pk 억제제로서 (s)-n-메틸-8-(1-((2'-메틸-[4,5'-비피리미딘]-6-일)아미노)프로판-2-일)퀴놀린-4-카복스아미드 및 이의 듀테로화된 유도체의 공결정

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130281431A1 (en) * 2012-04-24 2013-10-24 Vertex Pharmaceuticals Incorporated Dna-pk inhibitors
US20160083401A1 (en) * 2013-05-11 2016-03-24 Merck Patent Gmbh Arylquinazolines

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ELZBIETA PASTWA ET AL, "Wortmannin potentiates the combined effect of etoposide and cisplatin in human glioma cells", INTERNATIONAL JOURNAL OF BIOCHEMISTRY AND CELL BIOLOGY, GB, (2014-08-01), vol. 53, pages 423 - 431 *
U YILMAZ ET AL, "Carboplatin plus etoposide for extensive stage small-cell lung cancer: An experience with AUC 6 doses of carboplatin", INDIAN JOURNAL OF CANCER, IN, (2011-01-01), vol. 48, no. 4, page 454 *

Also Published As

Publication number Publication date
JP7113826B2 (ja) 2022-08-05
EP3554495A1 (en) 2019-10-23
US20190365896A1 (en) 2019-12-05
AU2017384134A1 (en) 2019-08-01
KR20190099253A (ko) 2019-08-26
ES3040063T3 (en) 2025-10-28
JP2020502182A (ja) 2020-01-23
CA3047449C (en) 2023-07-04
US11246929B2 (en) 2022-02-15
WO2018114776A1 (en) 2018-06-28
CA3047449A1 (en) 2018-06-28
EP3554495B1 (en) 2025-06-04
KR102607967B1 (ko) 2023-11-29

Similar Documents

Publication Publication Date Title
US20210100813A1 (en) Combination therapy for cancer using bromodomain and extra-terminal (bet) protein inhibitors
US20200368235A1 (en) Ibrutinib combination therapy
JP7288482B2 (ja) がんの処置のための、Ｎｏｔｃｈ阻害剤およびＣＤＫ４／６阻害剤の併用療法
JP7194022B2 (ja) Ｎｏｔｃｈ阻害剤とＰＤ－１またはＰＤ－Ｌ１阻害剤との併用療法
US9254299B2 (en) Administration of hypoxia activated prodrugs in combination with Chk1 inhibitors for treating cancer
JP7123806B2 (ja) 静止細胞標的化およびｅｇｆｒ阻害剤を用いた新生物の処置のための組み合わせ
WO2016055907A1 (en) Synergistic auristatin combinations
JP2020512977A (ja) Ｃｈｋ１阻害剤とｗｅｅ１阻害剤との組み合わせ
AU2017384134B2 (en) Combination of a protein kinase inhibitor and an additional chemotherapeutic agent
AU2021267213B2 (en) Pharmaceutical combination comprising TNO155 and nazartinib
EP2707001B1 (en) Method for treatment of solid malignancies including advanced or metastatic solid malignancies
JP2018513185A (ja) 共結晶組成物及びその医薬用途
KR20250121432A (ko) Mta-협력 prmt5 저해제를 사용한 암 치료
WO2020114348A1 (en) Methods for cancer therapy
CN113329749A (zh) 用于治疗葡萄膜黑色素瘤的联合疗法
US20190183893A1 (en) Low dose of sildenafil as an antitumor drug
CN110638802A (zh) Atca在制备治疗肿瘤的药物中的用途
RU2785997C1 (ru) Комбинация ингибитора протеинкиназы и дополнительного химиотерапевтического средства
EP1313459B1 (en) Polycyclic dianthraquinones as anti-cancer and anti-angiogenic agents
KR20250088371A (ko) Ezh2 저해제 및 jak3 억제제를 포함하는 암의 예방 또는 치료용 약학적 조성물
KR20220140723A (ko) 암의 치료를 위한 약제학적 조합
HK40061016A (en) Combination therapy for the treatment of uveal melanoma
Kimura Second Generation Abl Tyrosine Kinase Inhibitors and Novel Compounds to Eliminate the Bcr-Abl/T315I Clone

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)